BioSpace News Archive

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company plans to present preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers, during the American Association f

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced two upcoming virtual poster presentations introducing the first preclinical data from the JTX-1811 program and data on the characterization of treatment emergent ICOS hi CD4 T cells with vopratelimab and their association with durable clinical responses. These pos

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has commence

All Patients in Cohort 3 Demonstrate Increased Time to Hypoglycemia and a Substantial Reduction in Cornstarch Use Introduction of Continuous Glucose Monitoring Reveals Early Transgene Expression and Enables More Rapid Reduction in Cornstarch Ultragenyx to Host ASGCT Recap Investor Conference Call today at 8:30 a.m. Eastern Time NOVATO, Calif., May 15, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and comme

GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced acceptance of three presentations on pre-clinical data for its proprietary universal CAR-T platform (UniCAR) targeting acute leukemia and solid tumors at the 2020 Virtual Annual Meeting of the A

Beyond Air, Inc. announced that it has entered into a new common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC, a Chicago-based fundamentally focused, long-term institutional investor, for up to $40 million.

Luxembourg becomes the first country to launch a systematic nationwide testing as part of the Proactive Mitigation Program designed by its COVID-19 Task Force

Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies

T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge Artificial Intelligence (AI) capabilities to select patient-specific neoantigens

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, announced that two posters featuring Cybrexa’s pipeline will be presented at the American Association for Cancer Research Virtual Annual Meeting II, which will be held June 22-24, 2020.